Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II study of CT103A for treatment of relapsed/refractory multiple myeloma

Next Previous
Trial Profile

Phase Ib/II study of CT103A for treatment of relapsed/refractory multiple myeloma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Equecabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innovent Biologics; Nanjing IASO Biotherapeutics

Most Recent Events

  • 09 Oct 2019 New trial record
  • 02 Oct 2019 According to an IASO Biotherapeutics media release, the company has received National Medical Products Administration approval for an Investigational New Drug Application for CT103A an innovative therapy for the treatment of relapsed refractory multiple myeloma (rr/mm) patients and IASO Bio and Innovent will start a Phase Ib/II study to confirm the R2PD and move to phase II shortly after, with approval anticipated in 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top